The causes of retinoblastoma (RB) can now be described with considerable accuracy, although many details are still unclear. Understanding the genetic changes leading to RB has provided an awareness of general mechanisms of cancer development and ' progression, previously only suspected. From the basic understanding have come new diagnostic technologies that are now ready to be applied directly to RB patients and their families, and a rational approach, based on this understanding, will help us to develop new therapies that avoid the severe complica tions of conventional treatment.
MUTATIONS OF THE RBI GENE INITIATE RB TUMOURS
The RBI gene was identified because mutations in both alleles result in RB.1.2 All children with bilateral RB have a germ line mutation in RBI and develop tumours when the second, normal allele is lost or mutated. The non-heritable RB tumours arise when both alleles are mutated in one ret inoblast in an individual with normal RBI alleles; these events are each so rare, that the tumour is always unifocal and unilateral. However, 15% of the unilaterally affected patients do have a germline RBI mutation. Although bilaterally affected patients may inherit a defective RBI gene, most have no family history of RB and have new germ line mutations, proven in some cases.3,4.5 In these patients, the answer to the title question begins when poorly-defined factors cause that initial germline mutation. Cytogenetic6 and molecular ana lyses7.8.9 have shown that these new mutations arise more commonly on the paternal chromosome. In contrast, uni lateral tumours, in which both RBI alleles were mutated only in the somatic retinal cell that became the tumour, 
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show the initial mutation on either maternal or paternal chromosomes, ruling out somatic imprinting as a mech anism in RB tumours. The paternal germ line mutation of RB I may arise because of the opportunity for mutation in the many cell divisions of spermatogenesis, \0 or by increased exposure of fathers to mutagens. A case control study has shown a significant association of new germline RB with paternal employment in the military and metal industries. 1 1 .12 Consistent with accumulation of mutations in sperm, several studies have suggested a small paternal age effect in bilateral but not unilateral RB.13.14,15
Types of RBI mutations
The RBI gene was localised to chromosome 13 by the observation of a constitutional deletion of chromosome 13 in 3% to 5% of RB patients.16,17,18,19 These children have many abnormalities in addition to RB, for example, card iac abnormalities, mental retardation, extra digits and a characteristic facial appearance,20 depending on the size and extent of the chromosome 13 deletion. However, most patients with germline mutations affect ing only RBI are of normal intelligence and are otherwise normal in every way except for tumour formation. The smallest deletion was specifically localised to band 13q14 (l3qI4.1-13q14.3).21 The gene was designated 'RBI' to leave room for another, unmapped, gene 'RB2' in which mutations could also lead to RB tumours. It is now likely that all RB tumours are caused by RBI mutations.
Chromosomal localisation of RBi was refined by family studies linking a chromosome 13q 14 marker (este rase D) to the occurrence of RB.22,23,24 The first molecular clone of RB I was obtained by identifying that a unique 13q 14 DNA fragment was homozygously deleted in a few RB tumours. 1 This genomic DNA fragment was then used to obtain the cDNA of the RBI gene.2 RBi spans approxi mately 200 kb and contains 27 exons.25
Many RBI mutations in RB tumours and other cancers have been characterised,3.4.5,26,27,28 but a complete survey that might indicate 'hot spots' for mutation has not yet been reported. The mutations have been detected by vari ous technologies.3,4,5 Currently, the most efficient method to find unknown mutations appears to be screening for variations from normal by single-stranded conformation polymorphism29,3o of the PCR-amplified exons. The types of mutations leading to RB tumours include deletions, duplications, and point mutations (See figure 1) .
As long as one normal RBi allele is present, cells are normal. Although it has been shown in RB tumour cells that both alleles of RBi are expressed4 and contribute to the total cellular p 11O,RBI only one functional allele is required. The patient with one mutant RBi allele in every retinal cell has normal retinal development, but is highly predisposed to develop RB tumours.
Loss of the remaining normal chromosome 13 
commonly initiates RB
The malignancy is initiated when the only remaining normal RBi allele is lost, leaving the developing retinal cell with no normal RBi gene (See figure 1) . In more than 70% of RB tumours this involves chromosomal events resulting in loss of all or most of the normal chromosome 13. This process was demonstrated initially by esterase D studies/I elaborated by restriction fragment length poly morphism (RFLP) analysis32,33,34 and finally was con firmed by RBi mutation identification. 3, 4, 5, 26, 27 In the tumours, the mutant and normal chromosomes recombine to duplicate the region around the mutant RBi allele, while the normal allele is lost35 by loss of heterozygosity (LOH) (See Figure 1) . In 30% of RB, the second RBi mutation is a separate mutation different from the first4. The independent, multifocal RB tumours in a single patient each arise by different second RBi mutations.
The cell of origin of RB, the 'retinoblast' is an embryo nic cell of the retina that is uniquely susceptible to malig nant transformation by RBi mutations. Morphologically, RB tumour cells resemble developing retinal cells prior to differentiation into multiple retinal cell types,36,37 but the basis for the preferential impact of RBi mutation in developing retina is not known. When babies with germ line RBi mutations are examined at birth, most already have RB. However, about 30% with no tumours at birth develop multiple tumours in both retinas in the first year of life. The mean number of separate RB tumours arising in patients with germline RBi mutation is three to four. 38,39 After three years of age new RB tumours are rarely observed.40 Presumably, within the first few years of life, the normal, fully differentiated, retinal cells cease pro liferation, terminally differentiate, and can no longer form RB tumours. These children are at about a 40,000 times risk to develop RB tumours compared to a child with two normal RBi alleles. The process of LOH is presumably occurring in all tissues at a similar frequency. Non-retinal cells may tolerate loss of RBi without proliferating out of control, or RBi may be lethal to the cells, so that LOH does not demonstrate any phenotype. However, once malignancy of many other tissues is initiated by other fac tors, loss of RBi may contribute a relative growth advan tage and is frequently observed, particularly in tissue culture cell lines.
The product of RBI: properties, fu nction and mutant fo rms
What is the protein that is so critical in retinal develop ment? The product of the RBi gene is a 110 KD protein (pIIORBI) that is transported into the nucleus in all tissues and cell types studied.41,42,43.44 In resting normal cells (Go and early G1 of the cell cycle), only hypophosphorylated p llORBI is present.45,46,47 As cells begin to prepare for, and initiate DNA synthesis (late G1 and S phase of the cell cycle) many pllORBI serine and threonine amino acids become phosphorylated48,49 by the action of a cell-cycle kinase. 48 Since absence of p II ORBI leads to RB and cancer, the normal function of p 11 ORBI must promote non-prolifer ation. Therefore, the hypophosphorylated form that is present in resting cells is presumed to be the active form. This idea is supported by the observation that the proteins of the DNA tumour viruses that are essential for the virus to transform mammalian cells, do so, by binding to several mammalian proteins including hypophosphorylated, pI 1 ifBI50,5 1,52.53.54 presumably preventing the cells from remaining in a resting state. p 11 ORBI functions by interacting with other cellular pro teins55,56 to influence the activity of other genes. For example, activity of proliferation-promoting genes such as c_jos,57 c_myc, 58 and RBi itself, is influenced by pIIO.RBI The effect of pIIORBI on other genes may be determined by tissue and development-specific protein complexes that act on specific target DNA sequences59,60,61,62 in the regulatory regions of the genes whose activity is modified.
Initial reports indicated that replacement of functional pllORBI into tumour cells had a dramatic effect on growth and tumour formation in immune-deficient animals. 63, 64, 65 We have observed different results: there is no change in the growth rate or ability to form tumours of RB or breast cancer cells reconstituted with RBi. These reconstituted cells produce pI IifBI that shows normal features: the cor rect size, cell cycle-regulated hyperphosphorylation, and binding to the adenovirus transforming protein, Ela.66 The ability of the cells to grow in adverse conditions and regu lation of growth-promoting genes may be altered. All the cell lines tested have the secondary growth promoting mutations in other genes, that are not overridden by pIIO,RBI suggesting that RBi is a weak tumour suppressor gene. This would be consistent with the restricted cell types in which RBi mutations can initiate cancer. Careful examination of the previously published experiments reveals that the data also supports only a weak tumour sup pressor activity for p 11 O. RB I Most of the RB i mutations found to lead to RB cause a truncated, unstable, protein4 (P. Hamel, personal com munication), and no pIIORBI is detected in RB tumours. The tumour in the left eye proliferated to fill the vitreous cavity, showing to the parents a white pupillary rejtex, and leading to diagnosis of RB. The tumour in the right eye was of moderate size, overhanging the optic nerve at diagnosis. Although conventional treatment was radiotherapy, a trial of experimental chemotherapy with VM26 , vincristine, and high dose cyclosporin A was initiated. The tumour shrank to show its origin nasal to the optic nerve. Alter six treatments at 10 day intervals, the residual mass was translucent, partially calci f ied, and about 1/3 the original size. The residual was treated on three occasions with cryotherapy' through a conjunctival incision, freezing up to the nasal rim of the optic nerve. No further tumour grow occurred. Ultimate visual acuity was normal, and radiation therapy was avoided. Once a family's RBI mutation is identified, prenatal diagnosis can be offered. Since early diagnosed RB is rarely fatal,69 and in most cases blindness can be preven ted, few parents will select termination of pregnancy if the fetus is shown to have the mutation. However, diagnosis of the mutation at 36 weeks gestation has been suggested as justification for premature delivery, in order to treat RB earlier, saving more sight and reducing the morbidity of therapy. Ultimately, such individuals will increase the fraction of RB cases that are inherited, if they continue to reproduce.
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Clinical application of RBI mutation identification
ADDITIONAL MUTATIONS ARE RQUIRED FOR MALIGNANCY
Retinoma: too few mutations?
Even if LOH has resulted in absence of any norm al RBI allele or p 11 ORBI in a developing retinal cell, malignancy may still not result (See Figure I) Alternately, retinomas may be determined by the RBI mutations. The germline mutation of a patient with ret inoma is not yet described, but two families have been identified that showed fewer than expected RB tumours and had germline mutations in the regulatory region of RBI.30 It was proposed that such regulatory mutations might result in a small amount of normal p llO RB I, that would account for fewer than the usual number of tumours. Similar mutations could lead to retinoma.
When retinoma is documented in an individual. repeated clinical observations must be carried out to ensure that a cell within the retinoma does not further mutate to become proliferative, malignant RB. 83 Resistance to Chemotherapy: too many mutations?
The majority of cases treated by removal of the eye are cured of cancer,84 and the mortality from RB in countries with modem medicine is only 8%.85 However, if curative therapy is delayed, the RB tumour may grow into the optic nerve and enter the meningeal space to disseminate throughout the brain and spinal cord. Up to the present time, RB disseminated in the central nervous system has not been curable. Rarely, bone marrow metastases arise without brain involvement, and may be curable by inten sive treatment.R6 Many RB are controlled by radiotherapy, as long as less than half the ocular volume is involved, and no vitreous seeding has occurred.87 However, patients with germline RBI mutations have a several hundredfold risk of develop ing second primary neoplasms, including osteosarcoma, fibrosarcoma, soft tissue sarcoma, melanoma, brain tumour and others, and this risk is significantly increased by radiotherapy.88,89,9o,91 Therefore, unless radiotherapy is the only way to achieve useful vision, control of the cancer by other therapies such as photocoagulation and cryo therapy is preferable.
Intraocular RB tumours have not been extensively treated by chemotherapy. The drugs available had high toxicity, and systemic potential to also cause second malignancies.90 Now, however, we have shown good initial responses of intraocular RB tumours to relatively non-toxic, non-alkylating drugs, VM26 and vincristine. Moderate sized tumours can be shrunk to a size treatable by cryo-or phototherapy. If the tumours remain too large for these treatments however, they become resistant to the effects of the drugs.
The membrane glycoprotein, P170, prevents accumu lation of multiple classes of chemotherapeutic agents in cancer cells, and results in multidrug-resistance (MDR) of the tumour cells.92 Increased P170 expression in RB tumours correlates well with an MDR phenotype, both in vitro and in vivo. 93 Several approaches are being devel oped to specifically counteract P170 and increase the effectiveness of chemotherapy.
Competition for the P170 drug efflux pump, for example by high levels of drugs such as cyclosporin A,94 interference with P170 by blockers such as verapamil,95 or inactivation of P170 by specific agents such as mono clonal antibodies,92 have potential to improve therapy and cure rates for many cancers, including RB. By understand ing 'How RB tumours form', we may be able significantly improve prospects for children with RB. Proc. Nat'l. Acad. Sci. 
